Diversified Healthcare Trust (DHC) Q4 2025: SHOP NOI Jumps 27.6% as Portfolio Reset Unlocks Runway
DHC’s fourth quarter capped a transformative year, with SHOP segment NOI up double digits and leverage falling sharply as the company completed its large-scale operator transition and asset sale program. Management’s 2026 guidance points to further margin expansion, with internal growth and ROI-driven renovations prioritized over external acquisitions. Investors should watch for occupancy gains and continued deleveraging as the SHOP reset matures.
Summary
- SHOP Margin Expansion Accelerates: Operator transitions and pricing discipline drove material NOI and margin gains.
- Balance Sheet De-risked: Major asset sales and debt paydowns pushed maturities out and cut leverage.
- Internal Growth in Focus: Reinvestment in underutilized assets and organic NOI growth are the near-term priorities.
Performance Analysis
DHC’s Q4 results reflect a business model pivot: the company completed the transition of 116 SHOP (Senior Housing Operating Portfolio) communities to seven regional operators, resulting in sharp improvement in SHOP segment performance. SHOP NOI for the quarter grew 27.6% year-over-year, with full-year SHOP NOI up 31.3%. Same-property occupancy rose 90 basis points to 82.4%, and average monthly rates increased 5.8%, supporting a 230 basis point margin expansion. These operational gains came despite the disruption of large-scale operator handoffs, which management noted are now complete.
On the capital side, DHC executed $1.4 billion in financing and asset sales, including the disposition of 69 non-core properties for $605 million in 2025 alone. Proceeds fully repaid near-term debt, leaving no maturities until 2028 and reducing net debt to adjusted EBITDA from 11.2x to 8.1x. The medical office and life science segment saw occupancy rise to 91.2% and rent spreads on new leases averaging nearly 8% above prior rents, though segment NOI will step down in 2026 due to asset sales.
- SHOP NOI Margin Expansion: Margin rose 230 basis points YoY, driven by revenue growth and cost discipline.
- Deleveraging Outpaces Plan: Net debt to EBITDA fell by over three turns, with further reduction targeted.
- CapEx Moderation: 2025 capital spend declined 23%, with 2026 guidance calling for another 18% drop.
With operator transitions behind it and a clean balance sheet, DHC enters 2026 positioned for internal growth, with management guiding to further SHOP NOI and margin expansion, supported by a favorable demand backdrop and muted new supply.
Executive Commentary
"In 2025, we completed over $1.4 billion in capital markets activity principally focused on financing, asset sales, and the establishment of a $150 million undrawn credit facility... These efforts combined with the work of our dedicated asset management team resulted in full year consolidated NOI growth of 31.3%, a reduction in our leverage of over three terms, and no debt maturities until 2028."
Chris Bellotto, President and Chief Executive Officer
"We ended the quarter with approximately $255 million of liquidity... Our net debt to adjusted EBITDA RE declined materially from 11.2 times at the beginning of 2025 to 8.1 times, while adjusted EBITDA RE to interest expense improved from 1.1 times to 1.5 times over the course of the year."
Matt Brown, Chief Financial Officer and Treasurer
Strategic Positioning
1. SHOP Reset and Operator Transition
DHC completed the wind-down and transition of 116 SHOP communities to seven regional operators, aiming to leverage local expertise and unlock operational upside. Management is focused on property-specific business plans, advanced CRM rollout, and dynamic pricing to drive occupancy and rate growth. Early engagement with new operators is expected to yield incremental gains throughout 2026 as transitions mature.
2. Internal Growth and ROI Projects
Organic growth is the primary lever for 2026, with a pipeline to reposition underutilized space (notably former skilled nursing wings) into higher-acuity units. Management targets adding up to 500 units across 15 locations, with mid-teens unlevered ROI, prioritizing these projects over external acquisitions for their risk-adjusted return and ability to support continuum of care offerings.
3. Balance Sheet Strength and Capital Allocation
Major asset sales and debt paydowns have de-risked the balance sheet, pushing maturities out to 2028 and lowering leverage. CapEx discipline is a focus, with 2026 spend expected to drop another 18%. Management signaled that future dispositions will be selective and proceeds will be used to further reduce leverage or fund accretive internal projects.
4. Medical Office and Life Science Segment
This segment saw occupancy and rent spreads improve, but 2026 NOI will step down due to recent property sales. Leasing pipeline remains active, and management is optimistic on releasing prospects for key expiring leases, especially in strong life science markets like Fremont, California.
5. Dividend and Capital Return
Despite strong 2025 performance, management is not prioritizing a dividend increase near-term, preferring to focus on operational execution and further deleveraging. The board will review capital return as SHOP performance stabilizes and internal growth opportunities are realized.
Key Considerations
DHC’s strategic context is defined by a pivot to internal value creation, with the SHOP reset and balance sheet overhaul providing a foundation for margin expansion and cash flow growth. Execution on occupancy, rate, and ROI-driven renovations will dictate the pace of improvement.
Key Considerations:
- Operator Transition Execution: SHOP segment results will hinge on new operator integration and ability to drive lead-to-move-in conversion and margin lift.
- Occupancy and Pricing Trajectory: Sustained occupancy gains and rate increases are needed to deliver on 2026 guidance and support deleveraging.
- CapEx and ROI Project Delivery: Timely rollout of ROI renovations and disciplined capital allocation are key for internal growth and risk mitigation.
- Medical Office Lease-Up: Successful renewal or re-leasing of expiring medical office and life science leases will impact segment stability post-asset sales.
- Dividend Policy Patience: Management is holding off on capital return, prioritizing operational momentum and leverage reduction.
Risks
Key risks include potential delays in SHOP operator integration, slower-than-expected occupancy or rate growth, and challenges in re-leasing medical office space as large tenants roll off. The company’s reliance on internal growth heightens execution risk, while macro headwinds or unexpected expense inflation could pressure margins and cash flow. Management’s guidance assumes continued demand tailwinds and stable cost environment, which may not materialize if industry or economic conditions shift.
Forward Outlook
For Q1 and full-year 2026, DHC guided to:
- SHOP NOI of $175 to $185 million
- Medical office and life science NOI of $94 to $98 million
- Triple net lease NOI of $28 to $30 million
- Adjusted EBITDA RE of $290 to $305 million
- Normalized FFO of $0.52 to $0.58 per share
Management highlighted:
- Margin expansion in SHOP segment driven by occupancy, rate, and expense moderation
- CapEx reduction of over 18% at midpoint, supporting free cash flow
Takeaways
DHC’s Q4 report signals a business that has reset its foundation, with the SHOP operator transition and asset sales behind it and a clear focus on internal value creation and deleveraging. Execution on occupancy, rate, and ROI projects will determine if the company can deliver the margin and cash flow growth implied in 2026 guidance.
- SHOP Margin and NOI Gains: 2025 and Q4 results validate the SHOP reset, but sustained growth depends on new operator execution and internal project rollout.
- Balance Sheet Flexibility: Deleveraging and no maturities until 2028 provide a window for operational focus and selective capital recycling.
- Watch for Occupancy and Margin Trends: Investors should track quarterly progress on occupancy, rate, and margin as the SHOP transition matures through 2026.
Conclusion
DHC enters 2026 with a streamlined portfolio, improved balance sheet, and a clear focus on internal growth levers. The SHOP segment’s margin and NOI trajectory will be the key indicator of success as operator transitions settle and ROI projects are executed. Investors will want to monitor both the pace of internal improvement and management’s discipline on capital allocation and leverage reduction.
Industry Read-Through
DHC’s results underscore a broader trend in senior housing and healthcare REITs: operator transitions, portfolio pruning, and internal value creation are replacing external M&A as the primary growth levers. The muted new supply environment and demographic tailwinds support a constructive backdrop, but execution risk remains high for those undertaking large-scale operator resets. Medical office and life science landlords face similar dynamics, with asset sales and tenant churn impacting near-term NOI but offering balance sheet relief. Investors across the sector should watch for margin expansion and disciplined capital allocation as the key differentiators in 2026.